ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) specialty pharma firm, is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.88 per share.
Looking ahead, the full year income are expected at $ 3.59 per share on the revenues of $ 204.37 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 213.00 million ~ $ 223.00 million, where as bottomline are predicted in a range of $ 4.46 ~ $ 4.86 per share
Click Here For More Historical Outlooks Of ANI Pharmaceuticals, Inc.
Previous Quarter Performance
ANI Pharmaceuticals, Inc. reported income for the second quarter of $ 0.69 per share, from the revenue of $ 48.47 million. The quarterly earnings reduced 52.08 percent while revenues contracted 10.84 percent compared with the same quarter last year.
According to street consensus, ANIP was expected to report 2Q20 income of $ 0.85 per share from revenue of $ 46.93 million. The bottom line results missed street analysts by $ 0.16 or 18.82 percent, at the same time, top line results outshined analysts by $ 1.54 million or 3.28 percent.
Stock Performance
Shares of ANI Pharmaceuticals, Inc. traded up $ 0.06 or 0.21 percent on Wednesday, reaching $ 28.17 with volume of 53.40 thousand shares. ANI Pharmaceuticals, Inc. has traded high as $ 28.61 and has cracked $ 27.16 on the downward trend
The closing price of $ 28.17, representing a 12.44 % increase from the 52 week low of $ 25.00 and a 62.89 % decrease over the 52 week high of $ 75.75.
The company has a market capital of $ 346.92 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
ANI Pharmaceuticals, Inc. will be hosting a conference call at 10:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.anipharmaceuticals.com
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
